[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Ajani, J.A., D’Amico, T.A., Bentrem, D.J., et al. (2019) Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. The National Comprehensive Cancer Network, 17, 855-883.
|
[3]
|
Sun, J.M., Shen, L., Shah, M.A., et al. (2021) Pembrolizumab plus Chemotherapy versus Chemotherapy Alone for First-Line Treatment of Advanced Oesophageal Cancer (KEYNOTE-590): A Randomised, Placebo-Controlled, Phase 3 Study. Lancet, 398, 759-771. https://doi.org/10.1016/S0140-6736(21)01234-4
|
[4]
|
Luo, H., Lu, J., Bai, Y., et al. (2021) Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA, 326, 916-925. https://doi.org/10.1001/jama.2021.12836
|
[5]
|
Kojima, T., Shah, M.A., Muro, K., et al. (2020) Randomized Phase III KEYNOTE-181 Study of Pembrolizumab versus Chemotherapy in Advanced Esophageal Cancer. Journal of Clinical Oncology, 38, 4138-4148.
https://doi.org/10.1200/JCO.20.01888
|
[6]
|
Choueiri, T.K., Powles, T., Burotto, M., et al. (2021) Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England Journal of Medicine, 384, 829-841.
|
[7]
|
Wang, Z.X., Cui, C., Yao, J., et al. (2022) Toripalimab plus Chemotherapy in Treatment-Naïve, Ad-vanced Esophageal Squamous Cell Carcinoma (JUPITER-06): A Multi-Center Phase 3 Trial. Cancer Cell, 40, 277-288.E3.
|
[8]
|
Doki, Y., Ajani, J.A., Kato, K., et al. (2022) Nivolumab Combination Therapy in Advanced Esopha-geal Squamous-Cell Carcinoma. The New England Journal of Medicine, 386, 449-462.
|
[9]
|
Forde, P.M., Chaft, J.E., Smith, K.N., et al. (2018) Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. The New England Journal of Medi-cine, 378, 1976-1986. https://doi.org/10.1056/NEJMoa1716078
|
[10]
|
Amaria, R.N., Reddy, S.M., Tawbi, H.A., et al. (2018) Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma. Nature Medicine, 24, 1649-1654. https://doi.org/10.1038/s41591-018-0197-1
|
[11]
|
Schalper, K.A., Rodriguez-Ruiz, M.E., Diez-Valle, R., et al. (2019) Neoadjuvant Nivolumab Modifies the Tumor Immune Microenvironment in Resectable Glioblastoma. Na-ture Medicine, 25, 470-476.
https://doi.org/10.1038/s41591-018-0339-5
|
[12]
|
Ledford, H. (2011) Melanoma Drug Wins US Approval. Nature, 471, 561. https://doi.org/10.1038/471561a
|
[13]
|
Keir, M.E., Liang, S.C., Guleria, I., et al. (2006) Tissue Expression of PD-L1 Mediates Peripheral T Cell Tolerance. Journal of Experimental Medicine, 203, 883-895. https://doi.org/10.1084/jem.20051776
|
[14]
|
Sun, C., Mezzadra, R. and Schumacher, T.N. (2018) Regulation and Function of the PD-L1 Checkpoint. Immunity, 48, 434-452. https://doi.org/10.1016/j.immuni.2018.03.014
|
[15]
|
Chowdhury, P.S., Chamoto, K. and Honjo, T. (2018) Combina-tion Therapy Strategies for Improving PD-1 Blockade Efficacy: A New Era in Cancer Immunotherapy. Journal of Inter-nal Medicine, 283, 110-120.
https://doi.org/10.1111/joim.12708
|
[16]
|
Li, C., Zhao, S., Zheng, Y., et al. (2021) Preoperative Pembrolizumab Combined with Chemoradiotherapy for Oesophageal Squamous Cell Carcinoma (PALACE-1). European Journal of Cancer, 144, 232-241.
https://doi.org/10.1016/j.ejca.2020.11.039
|
[17]
|
Yang, H., Liu, H., Chen, Y., et al. (2018) Neoadjuvant Chemoradi-otherapy Followed by Surgery versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter,
Randomized, Open-Label Clinical Trial. Journal of Clinical Oncology, 36, 2796-2803.
https://doi.org/10.1200/JCO.2018.79.1483
|
[18]
|
Zheng, Y., Li, C., Yu, B., et al. (2021) Preoperative Pembroli-zumab Combined with Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Trial Design. JTCVS Open, 9, 293-299. https://doi.org/10.1016/j.xjon.2021.11.003
|
[19]
|
Chen, R., Liu, Q., Li, Q., et al. (2023) A Phase II Clinical Trial of Toripalimab Combined with Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (NEOCRTEC1901). eClinicalMedicine, 62, Article ID: 102118. https://doi.org/10.1016/j.eclinm.2023.102118
|
[20]
|
Provencio, M., Nadal, E., Insa, A., et al. (2020) Neoadjuvant Chemotherapy and Nivolumab in Resectable Non-Small-Cell Lung Cancer (NADIM): An Open-Label, Multicentre, Sin-gle-Arm, Phase 2 Trial. The Lancet Oncology, 21, 1413-1422.
https://doi.org/10.1016/S1470-2045(20)30453-8
|
[21]
|
Zhang, Z., Hong, Z.N., Xie, S., et al. (2021) Neoadjuvant Sintilimab plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm, Sin-gle-Center, Phase 2 Trial (ESONICT-1). Annals of Translational Medicine, 9, Article 1623. https://doi.org/10.21037/atm-21-5381
|
[22]
|
Yang, P., Zhou, X., Yang, X., et al. (2021) Neoadjuvant Camrelizumab plus Chemotherapy in Treating Locally Advanced Esophageal Squamous Cell Carcinoma Patients: A Pilot Study. World Journal of Surgical Oncology, 19, Article No. 333. https://doi.org/10.1186/s12957-021-02446-5
|
[23]
|
Topalian, S.L., Taube, J.M. and Pardoll, D.M. (2020) Neoadjuvant Checkpoint Blockade for Cancer Immunotherapy. Science, 367, eaax0182. https://doi.org/10.1126/science.aax0182
|
[24]
|
Xing, W., Zhao, L., Zheng, Y., et al. (2021) The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Ad-vanced Esophageal Squamous Cell Cancer—A Phase II Study. Frontiers in Immunology, 12, Article 772450. https://doi.org/10.3389/fimmu.2021.772450
|
[25]
|
Zheng, Y., Liu, X.B., Sun, H.B., et al. (2021) A Phase III Study on Neoadjuvant Chemotherapy versus Neoadjuvant Toripalimab plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909). Annals of Trans-lational Medicine, 9, Article 73.
https://doi.org/10.21037/atm-20-5404
|
[26]
|
Yamamoto, S., Kato, K., Daiko, H., et al. (2020) Feasibility Study of Nivolumab as Neoadjuvant Chemotherapy for Locally Esophageal Carcinoma: FRONTiER (JCOG1804E). Future On-cology, 16, 1351-1357.
https://doi.org/10.2217/fon-2020-0189
|